Inventor
HOLLADAY MARK W
US43 patents
⚠️ This page may combine multiple inventors who share the name “HOLLADAY MARK W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABBOTT LAB
19 patentsUS5948793ASep 7, 1999
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
ABBOTT LAB77 citations96
US5629325AMay 13, 1997
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ABBOTT LAB106 citations96
US6437138B1Aug 20, 2002
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ABBOTT LAB54 citations95
US5914328AJun 22, 1999
Heterocyclic ether compounds useful in controlling neurotransmitter release
ABBOTT LAB67 citations95
US5346907ASep 13, 1994
Amino acid analog CCK antagonists
ABBOTT LAB94 citations95
US5472958ADec 5, 1995
2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
ABBOTT LAB55 citations93
US6593335B1Jul 15, 2003
Potassium channel openers
ABBOTT LAB28 citations92
US6265417B1Jul 24, 2001
Potassium channel openers
ABBOTT LAB30 citations92
US6127386AOct 3, 2000
3-Pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
ABBOTT LAB47 citations92
US5733912AMar 31, 1998
7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
ABBOTT LAB35 citations92
US5340802AAug 23, 1994
Peptide analog type-B CCK receptor ligands
ABBOTT LAB47 citations91
US5270302ADec 14, 1993
Derivatives of tetrapeptides as CCK agonists
ABBOTT LAB23 citations89
US6274587B1Aug 14, 2001
Tricyclic dihydropyrimidine potassium channel openers
ABBOTT LAB8 citations73
US6133253AOct 17, 2000
3-Pyridyl enantiomers and their use as analgesics
ABBOTT LAB12 citations72
US6538000B1Mar 25, 2003
Tricyclic dihydropyrimidine potassium channel openers
ABBOTT LAB4 citations62
US6503935B1Jan 7, 2003
Imidazoles and related compounds as α1A agonists
ABBOTT LAB5 citations62
US6001849ADec 14, 1999
Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission
ABBOTT LAB6 citations62
US6645968B2Nov 11, 2003
Potassium channel openers
ABBOTT LAB5 citations61
US6403575B1Jun 11, 2002
3-Pyridyl enantiomers and their use as analgesics
ABBOTT LAB3 citations61
AMBIT BIOSCIENCES CORP
13 patentsUS9320739B2Apr 26, 2016
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP6 citations83
US8969587B2Mar 3, 2015
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP8 citations83
US8349851B2Jan 8, 2013
JAK kinase modulating compounds and methods of use thereof
AMBIT BIOSCIENCES CORP9 citations83
US9725465B2Aug 8, 2017
Biaryl acetamide compounds and methods of use thereof
AMBIT BIOSCIENCES CORP3 citations73
US10053430B2Aug 21, 2018
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP1 citations62
US9730937B2Aug 15, 2017
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP1 citations62
US8927711B2Jan 6, 2015
JAK kinase modulating compounds and methods of use thereof
AMBIT BIOSCIENCES CORP2 citations62
US9938261B2Apr 10, 2018
Heterocyclic compounds and methods of use thereof
AMBIT BIOSCIENCES CORP0 citations52
US9452167B2Sep 27, 2016
Heterocyclic compounds and methods of use thereof
AMBIT BIOSCIENCES CORP1 citations52
US8952058B2Feb 10, 2015
Heterocyclic compounds and methods of use thereof
AMBIT BIOSCIENCES CORP0 citations52
US9308207B2Apr 12, 2016
JAK kinase modulating compounds and methods of use thereof
AMBIT BIOSCIENCES CORP0 citations51
US9295672B2Mar 29, 2016
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
AMBIT BIOSCIENCES CORP0 citations51
US8952020B2Feb 10, 2015
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
AMBIT BIOSCIENCES CORP0 citations51
XENON PHARMACEUTICALS INC
5 patentsUS7335658B2Feb 26, 2008
Pyridazine derivatives and their use as therapeutic agents
XENON PHARMACEUTICALS INC59 citations97
US8030488B2Oct 4, 2011
Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents
XENON PHARMACEUTICALS INC34 citations92
US7456180B2Nov 25, 2008
Piperazine derivatives and their use as therapeutic agents
XENON PHARMACEUTICALS INC24 citations92
US7919484B2Apr 5, 2011
Combination therapy
XENON PHARMACEUTICALS INC10 citations83
US7754711B2Jul 13, 2010
Pyridazine derivatives and their use as therapeutic agents
XENON PHARMACEUTICALS INC2 citations62
HOLLADAY MARK W
2 patentsUS8703943B2Apr 22, 2014
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
HOLLADAY MARK W7 citations81
US8912324B2Dec 16, 2014
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
HOLLADAY MARK W1 citations60